Director/PDMR Shareholding

Director/PDMR Shareholding

Cambridge, UK, 17 December 2015: Horizon Discovery Group plc (LSE: HZD), the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, announces that today, Susan Searle, Non-executive Director, purchased 7,191 ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") at an average price of 137 pence per Ordinary Share for her Self-Invested Personal Pension fund. Following this purchase, Susan Searle's direct beneficial interest in the Company is 44,691 Ordinary Shares, representing 0.05% of the Company's total issued share capital.

ENDS

Notes to Editors

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Dr. Darrin Disley CEO / Richard Vellacott CFO

Tel: +44 (0) 1223 655580

Consilium Strategic Communications (Financial Media and Investor Relations)

Amber Fennell / Jessica Hodgson / Matthew Neal / Laura Thornton

Tel: +44 (0) 20 3709 5701

Email: [email protected]

Panmure Gordon (UK) Limited (NOMAD)

Corporate Finance: Freddy Crossley / Fabien Holler / Duncan Monteith

Broking: Tom Salvesen

Tel: +44 20 7886 2500

Zyme Communications (Trade and Regional Media)

Katie Odgaard

Tel: +44 (0)7787 502 947

Email: [email protected]

About Horizon Discovery Group plc www.horizondiscovery.com/

Horizon is a revenue-generating life science group supplying research tools to organisations engaged in genomics research and the development of personalised medicines. Horizon has a diverse and international customer base of over 1,200 organisations across more than 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Group supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.

Horizon's core capabilities are built around its proprietary translational genomics platform, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon offers over 20,000 catalogue products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These 'patients-in-a-test-tube' are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.

In addition, Horizon provides custom cell line and in vivo model generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, and contract research and custom screening services.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD", for further information please visit: www.horizondiscovery.com.